SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. The program began with a robotic cardiac surgery LIMA take-down performed using the SSi Mantra 3.0 system. The procedure was led by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, with support from the SS Innovations team.
This development matters because it demonstrates the SSi Mantra's capabilities in cardiac surgery, a complex and high-risk specialty. The successful LIMA take-down, a critical step in coronary artery bypass grafting, signals that the system can be used for advanced cardiac procedures. This could lead to broader adoption of robotic cardiac surgery in India and other markets, potentially improving patient outcomes through minimally invasive techniques.
The company's growth trajectory is notable. SS Innovations reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines. This rapid adoption reflects increasing global demand for robotic surgical solutions that offer precision and flexibility.
SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand the SSi Mantra into additional international markets. Achieving these regulatory milestones would open doors to the world's largest healthcare markets, significantly increasing the company's addressable market and competitive positioning.
"We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region," the company wrote in a LinkedIn post. "At SS Innovations International, Inc. we remain committed to enabling hospitals and surgeons with advanced robotic technology."
The launch at HCG Hospital also underscores the strategic importance of India as a hub for robotic surgery innovation. With a large population and growing healthcare infrastructure, India presents a significant opportunity for SS Innovations to demonstrate the clinical and economic benefits of its system. The company's focus on cardiac surgery, a field where robotic assistance can reduce recovery times and complications, could accelerate adoption among Indian hospitals.
Investors and industry observers will be watching how quickly SS Innovations can translate these installations into revenue and whether the expansion into new countries yields sustained growth. The company's ability to secure regulatory approvals in the U.S. and Europe will be critical to its long-term success.
For more details, see the full announcement. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. InvestorWire, a specialized communications platform, distributed this news as part of its press release syndication services. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides corporate communications solutions to public and private companies. For full terms of use, visit https://www.InvestorWire.com/Disclaimer.
